
...BIBLIOGRAPHY...

- Alarcon GS, Tracy IC, Blackburn WD Jr. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. *Arthritis Rheum* 1989;32:671-676.
- Anderson PA, West SG, O'Dell JR, et al. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. *Ann Intern Med* 1985;103:489-496.
- Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. *Lancet* 1997;350(9074):309-318; erratum *Lancet* 1998;35(9097):220.
- Cohen S, Rutstein J, Luggen M, et al. Comparison of the safety and efficacy of cyclosporine A and methotrexate in refractory rheumatoid arthritis: A randomized, multi-centered placebo-controlled trial. *Arthritis Rheum* 1993;36(suppl):S56. Abstract.
- Felts W, Yelin E. The economic impact of the rheumatic diseases in the United States. *J Rheum* 1989;16:869-884.
- Furst DE, Koehnke R, Burmeister LF, et al. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. *J Rheumatol* 1989;16:313-320.
- Jeurissen MEC, Boerbooms AMT, van de Putte LBA, et al. Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. A randomized, double-blind study. *Ann Intern Med* 1991;114:999-1004.
- Jeurissen MEC, Boerbooms AMT, van de Putte LBA, et al. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight week randomized, double-blind trial. *Arthritis Rheum* 1991;34:961-972.
- Kavanaugh A, Heudebert G, Cush J, et al. Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): A decision analysis model. *Semin Arthritis Rheum* 1996;25:297-307.
- Kremer JM. Safety, efficacy, and mortality in long-term cohort of patients with rheumatoid arthritis taking methotrexate: Follow up after a mean of 13.3 years. *Arthritis Rheum* 1997;40:984-985.
- Liang MH, Larson M, Thompson M, et al. Costs and outcomes in rheumatoid arthritis and osteoarthritis. *Arthritis Rheum* 1984;27:522-529.
- McKay J, Ray R, Weissman M, for the Lenercept 362 Study Group. A double-blind, randomized, 6 arm, parallel-group, dose finding, double-dummy, multi-center comparison of sTNF α 55-IgG (Ro 45-2081-Lenercept [LEN]) subcutaneous (SC) to reference treatment with oral methotrexate (MTX) and their combination in patients with rheumatoid arthritis (RA) (12 week dose finding efficacy/safety study). *Arthritis Rheum* 1998;41(suppl):S132. Abstract.
- Meenan RF, Yelin EH, Henke CJ, et al. The costs of rheumatoid arthritis: A patient-oriented study of chronic disease costs. *Arthritis Rheum* 1978;21:827-833.
- Möttönen T, Hannonen P, Leirisalo-Repo M, et al. Prediction of remission in early rheumatoid arthritis [abstract 1231]. *Arthritis Rheum* 1998;41(suppl):S238.
- O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. *N Engl J Med* 1996;334:1287-1291.
- O'Dell J. Combination DMARD therapy for rheumatoid arthritis: Apparent universal acceptance. *Arthritis Rheum* 1997;40(suppl):S50.
- O'Dell JR, Nepom BS, Haire C, et al. HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments. *Ann Rheum Dis* 1998;57:209-213.
- O'Dell JR, Paulsen G, Haire C, et al. Combination DMARD therapy with methotrexate (M)-sulfasalazine (S)-hydroxychloroquine (H) in rheumatoid arthritis (RA): Continued efficacy with minimal toxicity at 5 years [abstract 596]. *Arthritis Rheum* 1998;41 (suppl):S132.
- Paulus HE, Effer MJ, Ward JR, et al. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs, based on the findings in patients treated with placebo. *Arthritis Rheum* 1990;33:477-484.
- Prashker MJ, Meenan RF. The total costs of drug therapy for rheumatoid arthritis: A model based on costs of drug, monitoring, and toxicity. *Arthritis Rheum* 1995;38:318-325.
- Pincus T, Marcum SB, Callahan LF. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices, II: Second line drugs and prednisone. *J Rheumatol* 1992;19:1985-1994.
- Rau R, Herborn G, Menninger H, et al. Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12-month data of a double blind parallel study of 174 patients. *Br J Rheumatol* 1997;36:345-352.

...BIBLIOGRAPHY...

- Suarez-Almazor ME. Practice patterns in the management of rheumatoid arthritis. Increased use of combination therapy [abstract 722]. *Arthritis Rheum* 1998;41(suppl):S153.
- Thompson RN, Watts C, Edelman J, et al. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. *J Rheumatol* 1984;11:760-763.
- Tugwell P, Bombardier C, Strand Y, et al. Treatment of active rheumatoid arthritis with leflunomide improves functional activities and health related quality of life (HRQOL). *Arthritis Rheum* 1998;41(suppl):S154. Abstract
- Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. *N Engl J Med* 1995; 333:137-141.
- Verhoeven AC, Bibo JC, Boers M, et al. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: Randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. *Br J Rheumatol* 1998;37:1102-1109.
- Wang BWE, Balise RR, Fries JR. Frequency of two-DMARD combination in the treatment of rheumatoid arthritis (RA) [abstract 161]. *Arthritis Rheum* 1998; 41(suppl):S59.
- Weaver A, Caldwell J, Olsen N, et al. Treatment of active rheumatoid arthritis with leflunomide compared to placebo or methotrexate. *Arthritis Rheum* 1998; 41(suppl):S131. Abstract.
- Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. *N Engl J Med* 1985;312:818-822.
- Weinblatt ME, Kaplan H, Germain BR, et al. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six week, double-blind trial. *Arthritis Rheum* 1990;33:330-338.
- Weinblatt ME, Kaplan H, Germain BF, et al. Methotrexate in rheumatoid arthritis: A five-year prospective multicenter trial. *Arthritis Rheum* 1994;37:1492-1498.
- Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. *N Engl J Med* 1999;340:253-259.
- Weinblatt ME, Kremer JM, Coblyn JS, et al. Leflunomide plus methotrexate in refractory rheumatoid arthritis: A pilot study [abstract 974]. *Arthritis Rheum* 1997;40(suppl):S193.
- Weinblatt ME, Maier AL, Fraser PA, et al. Longterm prospective study of methotrexate in rheumatoid arthritis: Conclusion after 132 months of therapy. *J Rheumatol* 1998;25:238-242.
- Weinblatt ME, Polisson R, Blotner SD, et al. The effects of drug therapy on radiographic progression of rheumatoid arthritis: Results of a 36-week randomized trial comparing methotrexate and auranofin. *Arthritis Rheum* 1993;36:613-619.
- Weinblatt ME, Trentham DE, Fraser PA, et al. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. *Arthritis Rheum* 1988;31:167-175.
- Weinblatt ME, Weissman BN, Holdsworth DE, et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis: Eighty-four month update. *Arthritis Rheum* 1992;3:129-137.
- Williams HG, Willkens RF, Samuelson CO Jr, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. *Arthritis Rheum* 1985;28:721-730.